Locations
Copenhagen, Denmark
industry
Administrative Services · Biotechnology · DeepTech · Health · HR and Recruiting
Size
11-50 employees
Stage
Series A
founded in
2017
Antag Therapeutics is a biotechnology company focused on developing innovative peptide-based therapies to combat obesity and related cardiometabolic disorders. Leveraging decades of research from the University of Copenhagen, the company specializes in GIPR antagonists, inspired by a naturally occurring GIPR antagonist. Their first-in-class therapeutic peptides aim to address the critical need for complementary obesity treatments, targeting diverse patient needs and challenges such as accessibility and long-term adherence. With a strong emphasis on clinical development, Antag is positioned to transform the treatment landscape for obesity, backed by significant funding and a robust pipeline of therapies.
Something looks off?